Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat + Paclitaxel in Recurrent Ovarian Cancer
NCT02661815Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ricolinostat in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (4 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 2 years and Best Overall Response at 13 months. Started Jun 2016; status: terminated.
02
Drugs
ricolinostat
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02661815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661815.